DGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quest Diagnostics is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The business is fundamentally healthy and Q1 was solid, but the current setup is better described as fairly valued to mildly positive rather than an urgent buy. Since there is no AI Stock Picker or SwingMax buy signal today and the technicals are not bullish enough to confirm momentum, I would not press a new full-sized purchase at this price. If already owned, it is reasonable to hold; if not owned, wait for a better entry rather than buying immediately.
DGX is trading at 194.2, slightly below the pivot level of 198.142 and above support at 189.628. RSI_6 at 45.834 is neutral, showing no strong overbought or oversold condition. MACD histogram is -0.36 and still below zero, which means momentum remains mildly negative even though it is contracting. Moving averages are converging, suggesting price is compressing rather than trending strongly. The short-term pattern estimate is weak, with expected performance around -0.51% over the next week and -2.67% over the next month. Overall, the chart is mixed-to-neutral, not a clear breakout setup.
["Q1 revenue rose 9.16% YoY to 2.895B", "Q1 net income increased 14.61% YoY and EPS rose 15.46% YoY", "Gross margin improved slightly to 31.33%", "2026 revenue guidance was raised to $11.78B-$11.9B and adjusted EPS guidance to $10.63-$10.83", "Analyst target prices were broadly raised after the Q1 beat", "Hedge funds are buying, with buying activity up 1536.08% over the last quarter", "Options flow leans bullish based on lower put-call ratios"]
["MACD remains below zero, so momentum is still negative", "RSI is neutral, not signaling a strong entry point", "Price is below the pivot level, so near-term trend is not decisively bullish", "Short-term stock trend model points to weakness over the next week and month", "The company issued $500M of senior notes, which is acceptable strategically but adds financing activity that investors may not love", "Insiders are neutral with no notable buying trend", "No recent congress trading data is available", "No AI Stock Picker or SwingMax signal is present today"]
In Q1 2026, Quest Diagnostics posted strong growth. Revenue increased to 2.895B, up 9.16% year over year, showing healthy top-line expansion. Net income rose 14.61% to 251M, EPS climbed 15.46% to 2.24, and gross margin improved modestly to 31.33%. This is a good quarter, and it supports the case that the business is executing well. For a long-term investor, the growth trend is positive and the raised full-year guidance adds confidence.
Analyst sentiment has improved recently. Several firms raised price targets after Q1 results, including Truist to 225, UBS to 220, Baird to 229, BofA to 245, Barclays to 230, Evercore ISI to 225, and Jefferies to 225. Ratings are mixed overall, with Hold/Neutral still common, but the tone of recent commentary is clearly better after the earnings beat and raised guidance. Wall Street pros generally see good execution and upside to estimates, but the repeated Hold/Neutral labels suggest the stock is seen as solid rather than a must-buy.
